Oxford Nanopore received CE‑IVDR and UKCA marks for its GridIon Dx sequencer, its first IVD‑marked device in Europe and the U.K., and signaled initial clinical use through a BioMérieux partnership to run an AmPore‑TB assay for multidrug‑resistant tuberculosis. Management framed the regulatory stamps as a foundational step toward commercial clinical deployments in infectious disease. The company also projected stronger 2025 revenue growth driven by clinical and biopharma markets, signaling an intentional shift from research‑only applications toward regulated diagnostic revenue streams.